AbbVie Announces Topline Results From Its Phase 3 LUNA Study Of Atogepant For Preventive Treatment Of Menstrual Migraine In Adults; Atogepant Demonstrated Statistically Significant Reductions In Migraine Days Associated With Menstrual Period, Meeting Primary And All Eight Ranked Secondary Endpoints Versus Placebo

뉴스 본문을 불러오고 있어요.

AbbVie Announces Topline Results From Its Phase 3 LUNA Study Of Atogepant For Preventive Treatment Of Menstrual Migraine In Adults; Atogepant Demonstrated Statistically Significant Reductions In Migraine Days Associated With Menstrual Period, Meeting Primary And All Eight Ranked Secondary Endpoints Versus Placebo | 웨이프 WAPE

기사 요약

관련 종목

댓글 —